Spyre Therapeutics Inc. (SYRE) Financial Statements (2024 and earlier)

Company Profile

Business Address 221 CRESCENT STREET
WALTHAM, MA 02453
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:339,30055,71193,128146,27371,94974,500
Cash and cash equivalents188,89334,86315,14290,09519,25322,461
Short-term investments150,38420,84877,98656,17852,69652,052
Other undisclosed cash, cash equivalents, and short-term investments23    (13)
Receivables  375815   
Other undisclosed current assets2,2286,1724,9483,5162,5562,171
Total current assets:341,52862,25898,891149,78974,50576,671
Noncurrent Assets
Operating lease, right-of-use asset  3,4303,8064,2304,726
Property, plant and equipment  3,2204,5495,6422,3851,018
Restricted cash and investments3221,5531,8381,8421,500 
Other noncurrent assets96838421156750
Total noncurrent assets:3318,88611,03511,8298,6781,068
TOTAL ASSETS:341,85971,144109,926161,61883,18377,739
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,4966,54211,3547,5047,5234,246
Employee-related liabilities4,9883,7123,2732,643
Accounts payable17,4806773,3192,2543,154663
Accrued liabilities6,0165,8653,0471,5381,096940
Deferred revenue  5172,359  
Debt  1641827379 
Derivative instruments and hedges, liabilities1,390     
Other undisclosed current liabilities7,0927,5816,0138,91210,4575,993
Total current liabilities:31,97814,65620,14416,44318,35910,239
Noncurrent Liabilities
Long-term debt and lease obligation:   4,6085,1294,712 
Liabilities, other than long-term debt41,3106,1831,2332143172
Deferred revenue  2,1791,217  
Other liabilities   162143172
Operating lease, liability  4,0044,6085,1294,712
Derivative instruments and hedges, liabilities41,310     
Total noncurrent liabilities:41,3106,1835,8415,3434,74372
Total liabilities:73,28820,83925,98521,78623,10210,311
Temporary equity, carrying amount 84,555     
Equity
Equity, attributable to parent, including:184,01650,30583,941139,83260,08167,428
Common stock1065532
Additional paid in capital763,191475,971425,765415,824255,142184,314
Accumulated other comprehensive income (loss)302(48)(20)1151(27)
Accumulated deficit(764,414)(425,624)(341,809)(276,008)(195,115)(116,861)
Other undisclosed equity, attributable to parent184,927     
Other undisclosed equity      
Total equity:184,01650,30583,941139,83260,08167,428
TOTAL LIABILITIES AND EQUITY:341,85971,144109,926161,61883,18377,739

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues8862,32918,739  3,888
Gross profit:8862,32918,739  3,888
Operating expenses(243,189)(87,110)(84,388)(81,481)(80,334)(49,351)
Operating loss:(242,303)(84,781)(65,649)(81,481)(80,334)(45,463)
Nonoperating income (expense)(96,513)830(11)5882,0801,115
Investment income, nonoperating6,1478371115932,1431,172
Other nonoperating expense(19,130)(7)(122)(5)(63)(57)
Loss from continuing operations before income taxes:(338,816)(83,951)(65,660)(80,893)(78,254)(44,348)
Income tax expense (benefit)26136(141)   
Loss from continuing operations:(338,790)(83,815)(65,801)(80,893)(78,254)(44,348)
Loss before gain (loss) on sale of properties:(65,801)(80,893)(78,254)(44,348)
Net loss available to common stockholders, diluted:(338,790)(83,815)(65,801)(80,893)(78,254)(44,348)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(338,790)(83,815)(65,801)(80,893)(78,254)(44,348)
Comprehensive loss:(338,790)(83,815)(65,801)(80,893)(78,254)(44,348)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent350(28)(31)(40)7875
Comprehensive loss, net of tax, attributable to parent:(338,440)(83,843)(65,832)(80,933)(78,176)(44,273)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: